Skip to main content

Neurologic Disorder

0
Pipeline Programs
9
Companies
11
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Synchron
SynchronNY - Brooklyn
4 programs
Motor NeuroprosthesisN/A1 trial
Motor NeuroprosthesisN/A1 trial
StentrodeN/A3 trials
StentrodeN/A1 trial
Active Trials
NCT05035823Active Not Recruiting6Est. Sep 2026
NCT05041114Withdrawn0Est. Nov 2022
NCT07533903Not Yet Recruiting10Est. Nov 2027
+3 more trials
Ipsen
IpsenChina - Tianjin
1 program
Data collectionN/A1 trial
Active Trials
NCT03329872Completed976Est. Apr 2019
Synaptrix
SynaptrixNY - New York
1 program
Intervention/TreatmentN/A1 trial
Active Trials
NCT06169696Unknown6Est. Jan 2025
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Parent-Reported Symptom AssessmentN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Parent-Reported Symptom AssessmentN/A1 trial
Active Trials
NCT03849066Completed136Est. Aug 2022
Overland Therapeutics
Overland TherapeuticsChina - Shanghai
1 program
Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO BionicsN/A1 trial
Active Trials
NCT05652946Unknown200Est. Jan 2025
Martin Pharmaceuticals
1 program
neurologic rehabilitationN/A1 trial
Active Trials
NCT03233789Completed265Est. Dec 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
SynchronStentrode
SynchronStentrode
SynchronStentrode
SynaptrixIntervention/Treatment
Overland TherapeuticsTyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics
SynchronMotor Neuroprosthesis
SynchronMotor Neuroprosthesis
SynchronStentrode
Colorado TherapeuticsParent-Reported Symptom Assessment
Martin Pharmaceuticalsneurologic rehabilitation
IpsenData collection

Clinical Trials (11)

Total enrollment: 1,624 patients across 11 trials

NCT07533903SynchronStentrode

Functional Outcomes and Control Using Synchron BCI - Australia

Start: Apr 2026Est. completion: Nov 202710 patients
N/ANot Yet Recruiting
NCT07543367SynchronStentrode

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

Start: Apr 2026Est. completion: Dec 202910 patients
N/ANot Yet Recruiting
NCT07446114SynchronStentrode

Functional Outcomes and Control Using Synchron BCI - Canada

Start: Mar 2026Est. completion: Jul 202710 patients
N/ARecruiting
NCT06169696SynaptrixIntervention/Treatment

EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis

Start: Nov 2024Est. completion: Jan 20256 patients
N/AUnknown
NCT05652946Overland TherapeuticsTyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics

IISART (International Industry Society of Advanced Rehabilitation Technology) Advanced Rehabilitation Technology Study

Start: Oct 2022Est. completion: Jan 2025200 patients
N/AUnknown
NCT05035823SynchronMotor Neuroprosthesis

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Start: Apr 2022Est. completion: Sep 20266 patients
N/AActive Not Recruiting
NCT05041114SynchronMotor Neuroprosthesis

SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Start: Apr 2022Est. completion: Nov 20220
N/AWithdrawn
NCT03834857SynchronStentrode

SWITCH: Stentrode First-in-Human Study of Implantable BCI for Control of a Digital Device

Start: May 2019Est. completion: Jan 20225 patients
N/ACompleted
NCT03849066Colorado TherapeuticsParent-Reported Symptom Assessment

Parent-Reported Symptom Assessments in Children Taking Multiple Medications

Start: Apr 2019Est. completion: Aug 2022136 patients
N/ACompleted
NCT03233789Martin Pharmaceuticalsneurologic rehabilitation

Development and Validation of an ADL-score Based on FIM and EBI

Start: Nov 2015Est. completion: Dec 2017265 patients
N/ACompleted
NCT03329872IpsenData collection

Neuro-Orthopedic Registry of the University Hospital of Toulouse

Start: Nov 2014Est. completion: Apr 2019976 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,624 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.